Synthomer Balance Sheet Health
Financial Health criteria checks 1/6
Synthomer has a total shareholder equity of £928.8M and total debt of £853.9M, which brings its debt-to-equity ratio to 91.9%. Its total assets and total liabilities are £2.4B and £1.5B respectively. Synthomer's EBIT is £37.5M making its interest coverage ratio 0.6. It has cash and short-term investments of £182.6M.
Key information
91.94%
Debt to equity ratio
UK£853.90m
Debt
| Interest coverage ratio | 0.6x |
| Cash | UK£182.60m |
| Equity | UK£928.80m |
| Total liabilities | UK£1.47b |
| Total assets | UK£2.40b |
Recent financial health updates
Recent updates
Analysis Article • Aug 08
Analysts Have Lowered Expectations For Synthomer plc (LON:SYNT) After Its Latest Results
Shareholders will be ecstatic, with their stake up 39% over the past week following Synthomer plc 's ( LON:SYNT...
Narrative Update • Aug 03
SYNT: Higher Fair Value And Execution Risks Will Shape Future Earnings
Analysts have raised their price target on Synthomer to £0.92 from £0.62, citing updated assumptions for fair value, revenue growth, profit margins and future P/E as key factors supporting the new level. Analyst Commentary Recent research updates on Synthomer suggest that, while targets have been adjusted, many analysts remain cautious about the stock.
Narrative Update • Jul 20
SYNT: Recent Price Objective Revisions Will Shape A More Constructive Outlook
The Analyst Price Target on Synthomer has been adjusted from £3.48 to £2.00 per share, reflecting analysts' updated assumptions on fair value, discount rate, and earnings profile in light of recent price target increases from £0.62 to £0.92 and an additional £0.40 uplift cited in Street research. Analyst Commentary Recent Street research on Synthomer points to a more constructive tone, with bullish analysts revisiting their fair value assumptions and revising price targets.
Narrative Update • Jul 06
SYNT: Cost Actions And Execution On Plans Will Support Future Upside
Analysts have lifted their fair value estimate for Synthomer from £1.27 to £1.47, reflecting higher price targets from the Street and updated assumptions around revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent Street commentary on Synthomer points to a more constructive stance on the stock, with price targets moving higher and ratings generally sitting in the neutral range.Narrative Update • Jun 22
SYNT: Leadership Change And Higher Risk Profile Will Pressure Future Earnings
Analysts have lifted their price target on Synthomer by £0.40, citing updated assumptions around discount rates, revenue growth and future P/E that they view as better aligned with the company’s current risk and earnings profile. What’s in the News for Synthomer Synthomer announced that Chief Financial Officer Lily Liu plans to step down to become Executive Vice President and Chief Financial Officer at Umicore SA.Narrative Update • Jun 06
SYNT: Leadership Transition Will Intensify Concerns Over Future Margin Stability
Analysts have nudged Synthomer's fair value higher, lifting the implied price target from £0.59 to £0.62. This reflects refreshed assumptions on revenue growth, discount rate and future P/E.Narrative Update • May 04
SYNT: Bio-Based Shift Will Face Margin And Leadership Risks Ahead
Analysts have kept their Synthomer fair value target steady at £0.59. This reflects a view that a shift from a previous revenue contraction of 32.37% to expected growth of 2.61%, together with a slightly lower projected profit margin of 9.99%, leaves the overall valuation framework broadly unchanged.Narrative Update • Apr 20
SYNT: Cost Actions And Bio-Based Shift Will Support Future Margin Stability
Analysts have slightly reduced their price expectations for Synthomer, reflecting updated assumptions for a less pronounced revenue decline, a small reduction in forecast profit margins, and a modest adjustment to future P/E. Taken together, these changes leave their fair value estimate unchanged at £0.59 per share.Narrative Update • Apr 06
SYNT: Cost Cuts And Bio Based Shift Will Support Future Upside
Analysts have nudged their price target on Synthomer slightly, reflecting modest tweaks to assumptions around discount rate, profit margin and future P/E, while keeping the underlying fair value estimate broadly unchanged at £1.27. What's in the News Godavari Biorefineries Limited entered a partnership with Synthomer to develop bio-based alternatives to existing fossil-based monomers, targeting growing customer demand for lower carbon and more sustainable materials (Key Developments).Narrative Update • Mar 23
SYNT: Cost Actions And Bio-Based Partnership Will Support Future Margin Resilience
Analysts have adjusted their Synthomer price targets slightly to reflect updated views on revenue contraction, slightly higher profit margins, and a modestly lower future P/E, resulting in a revised fair value estimate of £0.59 per share. What's in the News Synthomer entered a partnership with Godavari Biorefineries Limited to develop bio-based alternatives to existing fossil-based monomers.Narrative Update • Mar 09
SYNT: Cost Actions And Bio Based Shift Will Support Earnings Recovery
Analysts have trimmed their price target on Synthomer from £1.34 to about £1.27, citing updated assumptions on revenue growth, profit margins and future P/E multiples as they reassess the balance of risk and reward. What's in the News Godavari Biorefineries Limited partnered with Synthomer to develop bio-based alternatives to existing fossil-based monomers, including commercialisation of bio-based butyl acrylate using bio-based butanol from GBL, aimed at supporting customer demand for lower carbon materials (Key Developments).Narrative Update • Feb 22
SYNT: Cost Actions And Bio-Based Shift Will Support Future Margin Resilience
Analysts have nudged their price target on Synthomer higher to £0.59. This reflects updated assumptions around slightly less severe revenue contraction and broadly unchanged profit margins and P/E expectations.Narrative Update • Feb 08
SYNT: Cost Actions And Margin Resilience Will Support A Stable Fair Value View
Analysts have nudged their fair value estimate for Synthomer to £0.59 from £0.55, citing revised assumptions around revenue growth, profit margins and future P/E as the key drivers of the updated price target. What's in the News Synthomer issued earnings guidance for the twelve months to 31 December 2025, with expected 2025 revenue of around £1.74b compared with £1.93b for 2024, described as in line with market expectations (Key Developments).Narrative Update • Jan 24
SYNT: Earnings Prospects Will Stabilise As Fair Value View Remains Intact
Analysts have adjusted their price targets on Synthomer, reflecting revised assumptions around revenue growth, profit margins and future P/E multiples. Together, these changes point to a recalibrated view of the company’s earnings potential within an unchanged fair value estimate of £0.55 per share.Narrative Update • Jan 10
SYNT: Self Help And 2026 Outlook Will Support Earnings Recovery
Analysts have trimmed their price expectations for Synthomer, with a lower fair value estimate and a reduced Street target to £1.02 from £1.12. This reflects updated views on revenue growth and earnings multiples while maintaining a broadly neutral stance on the shares.Narrative Update • Dec 24
SYNT Will Face Mounting Pressure As Earnings Recovery Outlook Deteriorates
The analyst price target for Synthomer has been reduced to £1.02 per share from £1.12, as analysts factor in slower revenue growth assumptions, despite slightly higher profit margin expectations and a marginally increased discount rate. Analyst Commentary Recent research updates highlight a cautious stance from bearish analysts, who have progressively lowered their price targets on Synthomer as they reassess the company’s growth trajectory and risk profile.Narrative Update • Dec 10
SYNT: Self-Help Actions Will Drive Earnings Recovery Despite Neutral Market Sentiment
Analysts have trimmed their price target on Synthomer slightly. This reflects a modest recalibration in fair value to approximately £1.34 per share following a series of recent target cuts that have reset expectations for the stock.Narrative Update • Nov 26
SYNT: Full-Year Self-Help Actions Will Drive Earnings Recovery Momentum
Analysts have revised their price target for Synthomer downward from GBp 112 to GBp 102. This change is attributed to adjustments to future valuation metrics and an updated earnings outlook.Narrative Update • Nov 07
SYNT: Future Gains Are Expected As End Markets Gradually Stabilize
Synthomer's analyst price target has been reduced from 112 GBp to 102 GBp. Analysts cite persistent end-market challenges and limited near-term prospects for earnings recovery as key factors behind the downward revision. Analyst Commentary Recent analyst coverage reflects a spectrum of perspectives regarding Synthomer's outlook, shaped by evolving market dynamics and the company's updated financial guidance.Narrative Update • Oct 24
Future Earnings And Recovery Prospects Will Remain Under Pressure Amid Market Challenges
Synthomer's fair value estimate has been revised downward from £1.54 to £1.38 per share. Analysts cite ongoing challenges in end markets and modest growth prospects following the company's recent interim results.Analysis Article • Aug 09
UK£1.57: That's What Analysts Think Synthomer plc (LON:SYNT) Is Worth After Its Latest Results
There's been a major selloff in Synthomer plc ( LON:SYNT ) shares in the week since it released its half-year report...Narrative Update • Aug 07
Sustainable Specialty Polymers Will Unlock New Global Opportunities
Despite a notable upgrade in revenue growth forecasts and a reduction in the forward P/E, Synthomer's consensus analyst price target has been revised down from £1.71 to £1.57. Valuation Changes Summary of Valuation Changes for Synthomer The Consensus Analyst Price Target has fallen from £1.71 to £1.57.
New Narrative • Mar 31
Chemical Realignment And Adhesives Expansion Will Build A Resilient Future
Shift to high-margin specialty chemicals and divestment of non-core operations are expected to enhance profitability.Analysis Article • Jan 08
Investors Aren't Entirely Convinced By Synthomer plc's (LON:SYNT) Revenues
Synthomer plc's ( LON:SYNT ) price-to-sales (or "P/S") ratio of 0.1x might make it look like a buy right now compared...Analysis Article • Oct 05
Synthomer plc (LON:SYNT) Screens Well But There Might Be A Catch
You may think that with a price-to-sales (or "P/S") ratio of 0.2x Synthomer plc ( LON:SYNT ) is a stock worth checking...Analysis Article • Aug 03
Calculating The Intrinsic Value Of Synthomer plc (LON:SYNT)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Synthomer fair value estimate is UK£2.63 With UK£2.46 share...Analysis Article • Jun 18
Synthomer (LON:SYNT) Has Debt But No Earnings; Should You Worry?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • May 25
Investors Still Aren't Entirely Convinced By Synthomer plc's (LON:SYNT) Revenues Despite 27% Price Jump
Synthomer plc ( LON:SYNT ) shares have continued their recent momentum with a 27% gain in the last month alone. Still...Analysis Article • Apr 20
Is Synthomer plc (LON:SYNT) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights Using the 2 Stage Free Cash Flow to Equity, Synthomer fair value estimate is UK£1.84 Current share price...Analysis Article • Mar 14
Even With A 45% Surge, Cautious Investors Are Not Rewarding Synthomer plc's (LON:SYNT) Performance Completely
Synthomer plc ( LON:SYNT ) shareholders would be excited to see that the share price has had a great month, posting a...Analysis Article • Feb 08
Should You Think About Buying Synthomer plc (LON:SYNT) Now?
While Synthomer plc ( LON:SYNT ) might not have the largest market cap around , it saw a double-digit share price rise...Financial Position Analysis
Short Term Liabilities: SYNT's short term assets (£847.9M) exceed its short term liabilities (£475.1M).
Long Term Liabilities: SYNT's short term assets (£847.9M) do not cover its long term liabilities (£999.2M).
Debt to Equity History and Analysis
Debt Level: SYNT's net debt to equity ratio (72.3%) is considered high.
Reducing Debt: SYNT's debt to equity ratio has increased from 77.8% to 91.9% over the past 5 years.
Debt Coverage: SYNT's debt is not well covered by operating cash flow (7.7%).
Interest Coverage: SYNT's interest payments on its debt are not well covered by EBIT (0.6x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/14 02:25 |
| End of Day Share Price | 2026/08/14 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Synthomer plc is covered by 18 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Katie Richards | Barclays |
| James Stewart | Barclays |
| Robert Bate | Barclays |